GB201818977D0 - Islet cell engraftment - Google Patents

Islet cell engraftment

Info

Publication number
GB201818977D0
GB201818977D0 GBGB1818977.9A GB201818977A GB201818977D0 GB 201818977 D0 GB201818977 D0 GB 201818977D0 GB 201818977 A GB201818977 A GB 201818977A GB 201818977 D0 GB201818977 D0 GB 201818977D0
Authority
GB
United Kingdom
Prior art keywords
islet cell
cell engraftment
engraftment
islet
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1818977.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Nottingham
University of Edinburgh
Original Assignee
University of Nottingham
University of Edinburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Nottingham, University of Edinburgh filed Critical University of Nottingham
Priority to GBGB1818977.9A priority Critical patent/GB201818977D0/en
Publication of GB201818977D0 publication Critical patent/GB201818977D0/en
Priority to PCT/GB2019/053291 priority patent/WO2020104802A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
GBGB1818977.9A 2018-11-21 2018-11-21 Islet cell engraftment Ceased GB201818977D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1818977.9A GB201818977D0 (en) 2018-11-21 2018-11-21 Islet cell engraftment
PCT/GB2019/053291 WO2020104802A1 (en) 2018-11-21 2019-11-20 Islet cell engraftment

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1818977.9A GB201818977D0 (en) 2018-11-21 2018-11-21 Islet cell engraftment

Publications (1)

Publication Number Publication Date
GB201818977D0 true GB201818977D0 (en) 2019-01-09

Family

ID=65024595

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1818977.9A Ceased GB201818977D0 (en) 2018-11-21 2018-11-21 Islet cell engraftment

Country Status (2)

Country Link
GB (1) GB201818977D0 (en)
WO (1) WO2020104802A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2541166A (en) * 2015-07-24 2017-02-15 Midatech Ltd Nanoparticle-based liver-targeting therapy and imaging

Non-Patent Citations (52)

* Cited by examiner, † Cited by third party
Title
ALWAHSH, S. M. ET AL., CELL. MOL. LIFE SCI., vol. 75, 2018, pages 1307 - 1324
ALWAHSH, S. M.; RASHIDI, H.; HAY, D. C.: "Liver cell therapy: is this the end of the beginning", CELL. MOL. LIFE SCI., vol. 75, 2018, pages 1307 - 1324, XP036457055, DOI: doi:10.1007/s00018-017-2713-8
ASHWELL, G.; MORELL, A. G.: "Adv Enzymol Relat Areas Mol Biol.", 1974, JOHN WILEY & SONS, INC., article "The Role of Surface Carbohydrates in the Hepatic Recognition and Transport of Circulating Glycoproteins", pages: 99 - 128
BARSHES, N. R.; WYLLIE, S.; GOSS, J. A.: "Inflammation-mediated dysfunction and apoptosis in pancreatic islet transplantation: implications for intrahepatic grafts", J. LEUKOC. BIOL., vol. 77, 2005, pages 587 - 97
BARTON, F. B. ET AL.: "Improvement in outcomes of clinical islet transplantation: 1999-2010", DIABETES CARE, vol. 35, 2012, pages 1436 - 45
BEER, H. D. ET AL.: "Expression and function of keratinocyte growth factor and activin in skin morphogenesis and cutaneous wound repair", J. INVESTIG. DERMATOLOGY. SYMP. PROC., vol. 5, 2000, pages 34 - 9
BIARNES, M. ET AL.: "Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia", DIABETES, vol. 51, 2002, pages 66 - 72
BRENNAN, D. C. ET AL.: "Long-Term Follow-Up of the Edmonton Protocol of Islet Transplantation in the United States", AM. J. TRANSPLANT., vol. 16, 2016, pages 509 - 517
BROOKS, A. M. ET AL.: "Attainment of metabolic goals in the integrated UK islet transplant program with locally isolated and transported preparations", AM. J. TRANSPLANT, vol. 13, 2013, pages 3236 - 43
CATALDO, L. R. ET AL.: "Prolonged Activation of the Htr2b Serotonin Receptor Impairs Glucose Stimulated Insulin Secretion and Mitochondrial Function in MIN6 Cells", PLOS ONE, vol. 12, 2017, pages e0170213
DOMB: "The Handbook of Biodegradable Polymers", HARWOOD ACADEMIC PUBLISHERS
FORBES, S. ET AL., GENE THER., vol. 5, 1998, pages 552 - 555
FORBES, S. ET AL.: "Islet transplantation from a nationally funded UK centre reaches socially deprived groups and improves metabolic outcomes", DIABETOLOGIA, vol. 58, 2015, pages 1300 - 8, XP035495493, DOI: doi:10.1007/s00125-015-3554-3
FORBES, S. ET AL.: "Retroviral gene transfer to the liver in vivo during tri-iodothyronine induced hyperplasia", GENE THER., vol. 5, 1998, pages 552 - 555, XP000946073, DOI: doi:10.1038/sj.gt.3300613
FORBES, S. ET AL.: "Validation of the BETA-2 Score: An Improved Tool to Estimate Beta Cell Function After Clinical Islet Transplantation Using a Single Fasting Blood Sample", AM. J. TRANSPLANT, vol. 16, 2016, pages 2704 - 13
FORBES, S. J. ET AL., GASTROENTEROLOGY, vol. 118, 2000, pages 591 - 8
FORBES, S. J. ET AL.: "Synergistic growth factors enhance rat liver proliferation and enable retroviral gene transfer via a peripheral vein", GASTROENTEROLOGY, vol. 118, 2000, pages 591 - 8, XP005138947, DOI: doi:10.1016/S0016-5085(00)70266-6
FORBES, S. J. ET AL.: "Tri-iodothyronine and a deleted form of hepatocyte growth factor act synergistically to enhance liver proliferation and enable in vivo retroviral gene transfer via the peripheral venous system", GENE THER., vol. 7, 2000, pages 784 - 9
FORBES, S.; SENIOR, P. A.; SHAPIRO, A. M. J.: "Islet transplantation in type 1 diabetes: moving forward", LANCET. DIABETES ENDOCRINOL., vol. 6, 2018, pages 516 - 517
FRANK, S. ET AL.: "Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing", J. BIOL. CHEM., vol. 270, 1995, pages 12607 - 13, XP002125696, DOI: doi:10.1074/jbc.270.21.12607
FREDENBERG, S.; WAHLGREN, M.; RESLOW, M.; AXELSSON, A.: "The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems—A review", INT. J. PHARM., vol. 415, 2011, pages 34 - 52, XP028099846, DOI: doi:10.1016/j.ijpharm.2011.05.049
GALA-LOPEZ, B. L. ET AL.: "Beta Cell Death by Cell-free DNA and Outcome After Clinical Islet Transplantation", TRANSPLANTATION, vol. 102, 2018, pages 978 - 985
HAMMOND, J. S. ET AL., J. HEPATOL., vol. 54, 2011, pages 279 - 287
HAMMOND, J. S. ET AL.: "Scaffolds containing growth factors and extracellular matrix induce hepatocyte proliferation and cell migration in normal and regenerating rat liver", J. HEPATOL., vol. 54, 2011, pages 279 - 287, XP028170004, DOI: doi:10.1016/j.jhep.2010.06.040
HAMMOND, J. S., J. HEPATOL., vol. 54, 2011, pages 279 - 287
HATHOUT, E. ET AL.: "In vivo imaging demonstrates a time-line for new vessel formation in islet transplantation", PEDIATR. TRANSPLANT., vol. 13, 2009, pages 892 - 7
HERING, B. J. ET AL.: "Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia", DIABETES CARE, vol. 39, 2016, pages 1230 - 40
HUANG, Z. ET AL.: "A Novel Solid-Phase Site-Specific PEGylation Enhances the In Vitro and In Vivo Biostabilty of Recombinant Human Keratinocyte Growth Factor 1", PLOS ONE, vol. 7, 2012, pages e36423
KANAK, M. A. ET AL.: "Inflammatory response in islet transplantation", INT. J. ENDOCRINOL., 2014, pages 451035
KIM; AKAIKE: "The Journal of Biological Chemistry", vol. 276, 2001, pages: 35312 - 35319
LABLANCHE, S. ET AL.: "Islet transplantation versus insulin therapy in patients with type 1 diabetes with severe hypoglycaemia or poorly controlled glycaemia after kidney transplantation (TRIMECO): a multicentre, randomised controlled trial", LANCET. DIABETES ENDOCRINOL., vol. 6, 2018, pages 527 - 537
LEHMANN-WERMAN, R. ET AL.: "Identification of tissue-specific cell death using methylation patterns of circulating DNA", PROC NATL ACAD SCI U S A., vol. 113, 2016, pages E1826 - 34, XP055436315, DOI: doi:10.1073/pnas.1519286113
LI, D.-S.; YUAN, Y.-H.; TU, H.-J.; LIANG, Q.-L.; DAI, L.-J.: "A protocol for islet isolation from mouse pancreas", NAT. PROTOC., vol. 4, 2009, pages 1649 - 52
LI, Y.; HUANG, G.; DIAKUR, J.; WIEBE, L. I.: "Targeted delivery of macromolecular drugs: asialoglycoprotein receptor (ASGPR) expression by selected hepatoma cell lines used in antiviral drug development", CURR. DRUG DELIV., vol. 5, 2008, pages 299 - 302
MCCRIMMON, R. J.; SHERWIN, R. S.: "Hypoglycemia in type 1 diabetes", DIABETES, vol. 59, 2010, pages 2333 - 9
MICHALOPOULOS, G. K.: "Liver regeneration after partial hepatectomy: critical analysis of mechanistic dilemmas", AM. J. PATHOL., vol. 176, 2010, pages 2 - 13
NICLAUSS, N. ET AL.: "Influence of donor age on islet isolation and transplantation outcome", TRANSPLANTATION, vol. 91, 2011, pages 360 - 6
PAPAS, K. K.; SUSZYNSKI, T. M.; COLTON, C. K.: "Islet assessment for transplantation", CURR. OPIN. ORGAN TRANSPLANT., vol. 14, 2009, pages 674 - 82
QI, M. ET AL.: "Five-year follow-up of patients with type 1 diabetes transplanted with allogeneic islets: the UIC experience", ACTA DIABETOL., vol. 51, 2014, pages 833 - 43, XP035398871, DOI: doi:10.1007/s00592-014-0627-6
RAVEN, A. ET AL.: "Cholangiocytes act as facultative liver stem cells during impaired hepatocyte regeneration", NATURE, vol. 547, 2017, pages 350 - 354
ROTHER, K. I.; HARLAN, D. M.: "Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus", J. CLIN. INVEST., vol. 114, 2004, pages 877 - 83
RYAN, E. A. ET AL.: "Five-year follow-up after clinical islet transplantation", DIABETES, vol. 54, 2005, pages 2060 - 9
SAITO, Y.; CHAN, N. K.; HATHOUT, E.: "Partial hepatectomy improves the outcome of intraportal islet transplantation by promoting revascularization", ISLETS, vol. 4, 2012, pages 138 - 44
SENALDI, G. ET AL.: "Keratinocyte growth factor protects murine hepatocytes from tumor necrosis factor-induced apoptosis in vivo and in vitro", HEPATOLOGY, vol. 27, 1998, pages 1584 - 91
SHAPIRO, A. M. J. ET AL.: "Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen", N. ENGL. J. MED., vol. 343, 2000, pages 230 - 238, XP002220559, DOI: doi:10.1056/NEJM200007273430401
SHIMODA, M. ET AL., DIABETOLOGIA, vol. 53, 2010, pages 1669 - 79
SHIMODA, M.; CHEN, S.; NOGUCHI, H.; MATSUMOTO, S.; GRAYBURN, P. A.: "In vivo non-viral gene delivery of human vascular endothelial growth factor improves revascularisation and restoration of euglycaemia after human islet transplantation into mouse liver", DIABETOLOGIA, vol. 53, 2010, pages 1669 - 79, XP019836173
SUDO, T. ET AL.: "Hepatic regeneration promotes engraftment of intraportally transplanted islet cells", SURGERY, vol. 137, 2005, pages 612 - 9, XP004909898, DOI: doi:10.1016/j.surg.2005.02.007
SWEET, I. R. ET AL.: "Glucose-stimulated increment in oxygen consumption rate as a standardized test of human islet quality", AM. J. TRANSPLANT, vol. 8, 2008, pages 183 - 92
TAMAT; LANGER, JOURNAL OF BIOMATERIALS SCIENCE POLYMER EDITION, vol. 3, 1992, pages 315 - 353
TRIPATHI, D. ET AL.: "A TLR9 agonist promotes IL-22-dependent pancreatic islet allograft survival in type 1 diabetic mice", NAT. COMMUN., vol. 7, 2016, pages 13896
YOON, J. J.; NAM, Y. S.; KIM, J. H.; PARK, T. G.: "Surface immobilization of galactose onto aliphatic biodegradable polymers for hepatocyte culture", BIOTECHNOL. BIOENG., vol. 78, 2002, pages 1 - 10, XP055561464, DOI: doi:10.1002/bit.10239

Also Published As

Publication number Publication date
WO2020104802A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
IL267616A (en) Immunoengineered pluripotent cells
GB2591929B (en) Engineered regulatory T Cell
IL279871A (en) Cells differentiated from immunoengineered pluripotent cells
GB2577114B (en) Battery
GB201813178D0 (en) Cell
PL3654417T3 (en) Battery
GB201712733D0 (en) Methods & cells
GB201803079D0 (en) Cell
GB2577261B (en) Battery
EP3883014A4 (en) Solid battery
IL281531A (en) Insulin-producing cells
GB201819540D0 (en) T cell modification
PL3836173T3 (en) Reactor
GB201815190D0 (en) Battery compartent
EP3894614C0 (en) Electrochemical reactor
CA184764S (en) Storage case
GB201818625D0 (en) Battery
GB201807693D0 (en) Cell
GB201810123D0 (en) Cell selection procedures
CA201678S (en) Battery
CA192998S (en) Battery enclosure
GB201818977D0 (en) Islet cell engraftment
GB201816399D0 (en) Cell
GB201805918D0 (en) Cell
GB201804917D0 (en) Battery

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)